Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02376699 · ClinicalTrials.gov registry record · Phase 1
Safety Study of SEA-CD40 in Cancer Patients
A Phase 1 study, sponsored by Seagen.
- Terminated
- Registry status
- Phase 1
- Development phase
- 159
- Enrollment target
NCT02376699 is a Phase 1 study that was terminated before completion, run by Seagen. The registered enrollment target is 159 participants.
The verdict
NCT02376699, a Phase 1 study, was terminated before completion, sponsored by Seagen.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 159 participants
- Enrollment target
Study Summary
This study is being done to find out if SEA-CD40 is safe and effective when given alone, in combination with pembrolizumab, and in combination with pembrolizumab, gemcitabine, and nab-paclitaxel. The study will test increasing doses of SEA-CD40 given at least every 3 weeks to small groups of patients. The goal is to find the highest dose of SEA-CD40 that can be given to patients that does not cause unacceptable side effects. Different dose regimens will be evaluated. Different methods of administration may be evaluated. The pharmacokinetics, pharmacodynamic effects, biomarkers of response, and antitumor activity of SEA-CD40 will also be evaluated.
Interventions
- DRUG Pembrolizumab
- DRUG Gemcitabine
- DRUG Nab-paclitaxel
- DRUG Intravenous (IV) SEA-CD40
- DRUG Subcutaneous (SC) SEA-CD40
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 159 participants |
| Start Date | 2015-02-28 |
| Est. Completion | 2023-04-14 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02376699
The ClinicalTrials.gov registry entry for NCT02376699 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 159 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Seagen, which has 84 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Pembrolizumab is the first listed.
NCT02376699 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02376699 about?
NCT02376699 is a clinical study titled "Safety Study of SEA-CD40 in Cancer Patients". This study is being done to find out if SEA-CD40 is safe and effective when given alone, in combination with pembrolizumab, and in combination with pembrolizumab, gemcitabine, and nab-paclitaxel. The study will test increasing doses of SEA-CD40 given at least every 3 weeks to small groups of patient...
What is the current status of trial NCT02376699?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 159 participants. The study started on 2015-02-28. Estimated completion is 2023-04-14.
What interventions are being tested in trial NCT02376699?
The interventions under investigation include: Pembrolizumab (DRUG), Gemcitabine (DRUG), Nab-paclitaxel (DRUG), Intravenous (IV) SEA-CD40 (DRUG), Subcutaneous (SC) SEA-CD40 (DRUG).
Who is sponsoring clinical trial NCT02376699?
This trial is sponsored by Seagen, which has 84 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.